Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vidofludimus · IMU-838, NSC-717824

Small molecule · Inhibitor of dihydroorotate dehydrogenase (DHODH) · developed by Immunic

Phase 3 Most advanced trial
IMUX Developer
3 Registered trials

What is Vidofludimus?

Vidofludimus is an orally bioavailable inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), which blocks de novo pyrimidine synthesis in activated lymphocytes and reduces release of inflammatory cytokines such as IL-17 and IFN-gamma. It is studied in relapsing-remitting multiple sclerosis and COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IMU-838, NSC-717824
Drug type
Small molecule
Targets
dihydroorotate dehydrogenase (DHODH)
Mechanism
Inhibitor of dihydroorotate dehydrogenase (DHODH)
Pathways
de novo pyrimidine synthesis, pro-inflammatory cytokine release (IL-17, IFN-gamma)
Therapy area
Immunology, Infectious disease
Developer
Immunic AG (IMUX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
8Y1PJ3VG81

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05134441 Phase 3 Multiple Sclerosis Active not recruiting IMUX
NCT04379271 Phase 2/3 COVID-19 Completed IMUX
NCT03846219 Phase 2 Relapsing-Remitting Multiple Sclerosis (RRMS) Active not recruiting IMUX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Sclerosis, Relapsing-RemittingRelapsing-Remitting Multiple Sclerosis (RRMS)COVID-19

Other drugs acting on DHODH

More from Immunic

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMUX page.

Follow IMUX, the company behind Vidofludimus

See IMUX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMUX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.